Harrow Health, Inc. (HROW)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 49 | 72 | 89 | 130 | 200 | 272 | 276 | 350 |
| Operating profit | $m | 39 | - | ||||||
| Net profit | $m | -3 | -18 | -14 | -24 | -17 | -5 | -37 | -3 |
| EPS reported | $ | -0.14 | -0.99 | ||||||
| Operating cashflow per share | $ | 1.19 | 0.17 | ||||||
| Capex per share | $ | 0.03 | 0.02 | ||||||
| FCF per share | $ | 1.16 | 0.15 | ||||||
| Free cash flow | $m | 43 | 6 | ||||||
| Net debt | $m | 171 | 208 | ||||||
| Book value equity | $m | 52 | 15 | ||||||
| Book value per share | $ | 1.43 | 0.41 | ||||||
| Number of shares | m | 36.76 | 37.35 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 34.35 | 118.50 | ||||||
| P/S LTM | x | 6.61 | 6.54 | ||||||
| P/FCF LTM | x | 42.12 | 316.79 | ||||||
| EV/EBITDA LTM | x | 47.88 | 441.74 | ||||||
| EV/Sales LTM | x | 7.27 | 6.20 | ||||||
| Earnings Yield LTM | % | -0.29% | -2.49% | ||||||
| FCF Yield | % | +2.37% | +0.32% | ||||||
| Quality | |||||||||
| ROE | % | -9.80% | -103.86% | ||||||
| ROIC | % | +12.70% | +1.81% | ||||||
| Operating margin | % | +14.18% | +2.07% | ||||||
| Gross margin | % | +75.05% | +73.28% | ||||||
| FCF/Sales | % | +15.70% | +2.06% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +36.41% | +38.06% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | +337.64% | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.17 | 0.02 | ||||||
| Net Debt/EBITDA | x | 4.33 | 48.37 | ||||||
| EBIT/Net interest | x | 1.60 | 0.25 | ||||||
| Net debt/market cap | % | +13.55% | +19.59% | ||||||
| Net debt/Equity | x | 3.26 | 13.72 | ||||||
| Gross debt/equity | x | 4.80 | 19.79 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free